NCT06328283尚未招募不适用
The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of GLutamine Synthetase and BCLAF1 in Diagnosis of Hepatocellular in Cirrhotic Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- glutamine synthetase
研究概览
简要总结
Hepatocellular carcinoma (HCC) is the most prominent kind of liver cancer, accounting for 85% of primary liver malignancies. It is a very aggressive tumor, having a terrible prognosis and poor survival rate HCC is ranked as the sixth most common type of cancer and the third leading cause of cancer-related mortalities world wide.
HCC incidences arise in complications associated with chronic liver disease like cirrhosis, endemic hepatitis B virus (HBV)/hepatitis C virus (HCV) infections, non alcoholic fatty liver disease (NAFLD), and alcohol-related liver disease (Torre, 2015).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A total 90 adult patients with liver cirrhosis attending the outpatient clinic or in patient section of the department of tropical medicine and gastroenterology at Sohag University Hospital will be included in the study. Patients will be divided into two groups:
- •The study group will include 45 patients diagnosed with liver cirrhosis with absence of hepatic focal lesion as control group. Cirrhosis will be determined according to clinical , sereological ,radiological findings.
- •The study group will include 45 patient with HCC on top of liver cirrhosis .All causes of liver cirrhosis will be accepted .HCC will be assessed by triphasic CT or MRI or histological validation .In these group we will take patients with liver cirrhosis with early hepatocellular carcinoma that defined as tumors smaller than 3cm and three or fewer in number at stage A according to BCLC staging also sometimes it includes solitary tumors up to 5 cm in size as defined in the Milan criteria. Both very early and early stage tumors are relatively small but both are hyper vascular in arterial phase.
排除标准
- •Non cirrhotic patients.
- •Patients with distant metastasis.
- •Patients aged below18 years.
- •Patients with other malignancy rather than HCC.
- •Patients with late stage of HCC.
结局指标
主要结局
glutamine synthetase
时间窗: 1 year
to detect early HCC IN CIRRHOTIC
次要结局
未报告次要终点
研究者
Esraa Safwat Abdelrahman
assisstant lecturer in tropical medicine- sohag university
Sohag University
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Noninvasive Surrogate Marker for Advanced Hepatocellular Carcinoma Response to Concurrent Chemoradiotherapy: MR Perfusion, Contrast Enhanced Ultrasound and BiomarkersAdvanced Adult Hepatocellular CarcinomaNCT01336452Yonsei University30
撤回
1 期
A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver TransplantationRecurrent Hepatocellular CarcinomaNCT03634683Lion TCR Pte. Ltd.
已完成
不适用
Yliver as a Test to Early Diagnose HCCHepatocellular CarcinomaNCT03767764Corporacion Parc Tauli190
已完成
不适用
HCC Screening Using DNA Methylation Changes in ctDNAHepatocellular CarcinomaNCT03483922HKGepitherapeutics403
Unknown
不适用
TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 TrialTransarterial ChemoembolizationHepatocellular CarcinomaNCT04531228Yunfei Yuan60